Fresh Equities
Offers
Learn
LIVING CELL TECHNOLOGIES LIMITED

INVESTOR PRESENTATION - LIVING CELL TECHNOLOGIES LIMITED

ASX:LCT

LIVING CELL TECHNOLOGIES LIMITED

Health Care

Living Cell Technologies (LCT) develops cell therapies to treat diseases with high unmet clinical needs. The Australasian biotechnology company is a global pioneer in the field of cell encapsulation and implantation for human therapeutics. To date, the company has taken two therapeutic candidates into clinical development: DIABECELL for the treatment of type 1 diabetes and NTCELL , which is in Phase I clinical trials in New Zealand for the treatment of Parkinson's disease. Former Names --

Read more

Market Cap

9.14m

Price at Close

$0.016

4w avg. Volume

517.34k

4w avg. Turnover

$9.24k

Announcements
announcementt+2 movementdate
  • Notification of Change of Auditor

    Company Administration

  • -

    18 Sep 2020

-

18 Sep 2020
  • Preliminary Final Report and 2020 Financial Statements

    Periodic Reports · Market sensitive

  • -10.00%

    31 Aug 2020

-10.00%

31 Aug 2020
  • LCT founder Sir Robert Elliott dies

    Shareholder Details

  • +12.50%

    21 Aug 2020

+12.50%

21 Aug 2020
  • Amended Appendix 4C

    Commitments test entity quarterly reports · Market sensitive

  • 0.00%

    30 Jul 2020

0.00%

30 Jul 2020
  • Quarterly Activity Report and Appendix 4C

    Commitments test entity quarterly reports · Market sensitive

  • 0.00%

    30 Jul 2020

0.00%

30 Jul 2020
  • Response to ASX Aware Query

    ASX Query · Market sensitive

  • +6.67%

    12 Jul 2020

+6.67%

12 Jul 2020
  • Change of Director's Interest Notice - K Taylor

    Shareholder Details

  • -7.14%

    08 Jul 2020

-7.14%

08 Jul 2020
  • LCT Newsletter - July 2020

    Periodic Reports

  • -22.22%

    03 Jul 2020

-22.22%

03 Jul 2020
  • Appendix 4C - quarterly

    Commitments test entity quarterly reports · Market sensitive

  • +21.43%

    29 Apr 2020

+21.43%

29 Apr 2020
  • LCT Covid-19 Business Impact Update

    Periodic Reports

  • -7.69%

    17 Apr 2020

-7.69%

17 Apr 2020
Market Data

Current Price

$0.016

52WK HIGH

$0.024

52WK LOW

$0.009

1YR RETURN

-15.79%

1YR RETURN VS. SECTOR

-45.97%

90 DAY RETURN

+45.45%

ASX RANK

1,701

/2,019

SECTOR RANK

42

/47

SHARES OUTSTANDING

571.44m
ASX:LCT

LIVING CELL TECHNOLOGIES LIMITED

Health Care

Living Cell Technologies (LCT) develops cell therapies to treat diseases with high unmet clinical needs. The Australasian biotechnology company is a global pioneer in the field of cell encapsulation and implantation for human therapeutics. To date, the company has taken two therapeutic candidates into clinical development: DIABECELL for the treatment of type 1 diabetes and NTCELL , which is in Phase I clinical trials in New Zealand for the treatment of Parkinson's disease. Former Names --

Read more

Market Cap

9.14m

Price at Close

$0.016

4w avg. Volume

517.34k

4w avg. Turnover

$9.24k

ASX:LCT is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Support

Live Chat

Research
Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.